STTR Phase I: Developing an optical metabolic flow cytometer to screen T cell fitness for — NSF Award to SELIGHT, LLC (WI, $304,73
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a rapid diagnostic method for identifying patients that will benefit from Chimeric Antigen Receptor (CAR) T cell therapy. Chimeric Antigen Receptor T cell therapy is an emerging clinical method of producing last
| Award title | STTR Phase I: Developing an optical metabolic flow cytometer to screen T cell fitness for |
|---|---|
| Award ID | 2451768 |
| Awardee | SELIGHT, LLC |
| City | MADISON |
| State | WI |
| Amount obligated | $304,733 |
| Principal investigator | Amani Gillette |
| Program | STTR Phase I |
| Start date | 07/01/2025 |
| Abstract | The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a rapid diagnostic method for identifying patients that will benefit from Chimeric Antigen Receptor (CAR) T cell therapy. Chimeric Antigen Receptor T cell therapy is an emerging clinical method of producing lasting remission in cancer patients by re engineering patient’s own T cells. The therapy also remains under active investigation for other emerging applications. The T cells in nearly |
| Source | NSF Awards |
$799/mo
Try NSFGrants →